🇺🇸 FDA
Patent

US 12168681

Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

granted A61KA61K38/00A61K38/2013

Quick answer

US patent 12168681 (Il-2 variants with reduced binding to IL-2 receptor alpha and uses thereof) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K38/00, A61K38/2013, A61K45/06, A61P